Repligen posts investor presentation on planned BioLife Solutions acquisition at USD 31 a share - RGEN News | RalliesRepligen posts investor presentation on planned BioLife Solutions acquisition at USD 31 a share
R
RGEN• Quarterly update and results timing
- Repligen flagged Q2 revenue growth of about 12% reported and 13% organic.
- Full results are scheduled for July 28, 2026.
Planned BioLife Solutions acquisition
- Repligen unveiled a deal to buy BioLife Solutions for $31 per share, targeting a close in Q4 2026.
- Consideration totals $11.25 per share in cash and $19.75 per share in Repligen stock; 0.1442 Repligen shares per BioLife share.
- The transaction implies about $1.5 billion enterprise value; funding includes $564 million cash and 7,200,000 Repligen shares.
- Repligen expects more than $20 million of year-one synergies, rising to more than $30 million in year two.
TOI
•
